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Background: Various late-onset noninfectious pulmonary complications may occur after alloge-
neic hematopoietic stem cell transplantation (HSCT). Interstitial lung diseases (ILD) are often
overlooked, and few data are available.
Methods: We retrospectively analyzed the clinical features, pulmonary function tests, radio-
logical features and outcomes of allogeneic HSCT recipients who were diagnosed with a nonin-
fectious ILD and were managed in our center between 2001 and 2010.
Results: Forty patients were analyzed. The median time from transplant to ILD was 11.3
months. The donor hematopoietic stem cell source was peripheral blood stem cells in 75% of
the cases. Seventy percent of the patients had extra-thoracic chronic graft versus host disease
at ILD diagnosis. We identified two lung computed tomography (CT) scan patterns according to
the predominance of ground glass opacities or alveolar consolidations. Restrictive ventilatory
defect was the main pulmonary function pattern. Lung histology was available for seven pa-
tients and showed diffuse alveolar damage, non-specific interstitial pneumonia, organizing
pneumonia or lymphoid interstitial pneumonia. Thirty-five patients (87.5%) were treated with
systemic steroids. Thirteen patients died (32.5%), 10 of respiratory failure. The median survival
rate at 24 months was 61%.
Conclusion: This study highlights the existence of noninfectious post-allogeneic HSCT ILD and
provides new insights into the characteristics of these illnesses.
ª 2014 Elsevier Ltd. All rights reserved.ia
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Late onset noninfectious pulmonary complications
(LONIPCs) might follow allogeneic hematopoietic stem celltransplantation (HSCT) and have a significant effect on
patient outcomes [1e3]. Previous publications have
focused on bronchiolitis obliterans (BO), which is the most
common LONIPC [4e6]. Some epidemiological retrospective
studies [2,7e9] have reported interstitial lung diseases
(ILD) among LONIPCs. Although individual cases of post
allogeneic HSCT ILD have been published [10e13], no series
have described the spectrum of these ILD using an overall
pulmonologic approach. Post HSCT noninfectious ILD are
likely misdiagnosed and overlooked. Conversely to BO [6],
ILD is characterized by the presence of diffuse lung
parenchymal opacities on a CT scan. In the current prac-
tice, an infectious cause is first considered. Concomitantly,
the patient might be diagnosed with an extra thoracic graft
versus host disease (GVHD) and treated with corticoste-
roids. In this context, these patients are usually treated
with a combined treatment associating empirical anti-
microbiological drugs and steroids that may explain why
these noninfectious ILD are misdiagnosed.
The process of achieving a multidisciplinary diagnosis in
a patient with ILD requires close communication between
clinician, radiologist, and when appropriate, pathologist
[14]. The multidisciplinary approach usually allows to
determine whether the noninvasive approach based on
clinical, radiological, lung function, bronchoalveolar lavage
(BAL) and laboratory findings is informative enough or if a
lung biopsy is needed [14]. Besides idiopathic ILD, several
medical settings such as exposure or collagen vascular
diseases have been shown to cause ILD. In these contexts,
knowledge of the clinical characteristics of these ILD has
led to an improvement in their management with a dra-
matic decrease in the indications for lung biopsies [14e19].
In the setting of allogeneic HSCT, two pathological studies
identified 6 cases of diffuse alveolar damage (DAD) 8 cases
of organizing pneumonia (OP), one case of lymphoid
interstitial pneumonia (LIP) and 13 cases of non-classified
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surgical lung biopsies is, however, questionable: first, a
lung biopsy is an invasive and high-risk procedure in this
setting [22,23]; second, no correlation between patholog-
ical findings and prognosis exists for post allogeneic HSCT
ILD that would allow to guide the treatment; and third, the
efficient microbiological tools applied to samples obtained
from less invasive techniques such as BAL or nasal aspirate
often help differentiate ILD from infectious pneumonia
[24e26].
Because post HSCT ILD are infrequent, it was important
to retrospectively analyze the patients diagnosed with an
ILD to describe their clinical presentations based on the
pulmonary investigation techniques used in clinical practice
and to analyze the outcomes of these patients.
Patients and methods
This retrospective study was approved by the institutional
review board of the French learned society for respiratory
medicine CEPRO 2011-055. All of the allogeneic HSCT re-
cipients diagnosed with a noninfectious ILD in our center
between 2001 and 2010 were eligible for this study. In
addition, patients who underwent an allogeneic HSCT in
another French bone marrow transplantation department
and who were referred to our respiratory diseases depart-
ment for the management of an ILD were included. We
collected data from individual medical records.
Diagnosis of noninfectious ILD
A noninfectious ILD was diagnosed when infiltrative opaci-
ties were present on HRCT and 1) no pathogens were
identified in the respiratory samples (BAL and/or nasal
aspirate and/or sputum); and/or 2) no clinical or radiolog-
ical improvements were observed despite broad antimi-
crobial treatment; and/or 3) clinical and radiological
improvements occurred after initiating or increasing the
immunosuppressive treatment; and/or 4) no pathogens
were found on the lung biopsy (if it was performed).
Clinical characterization of ILD
As is conventional in pulmonology practice, ILD were
characterized by clinical symptoms, high-resolution
computed tomography (HRCT), pulmonary function testing
(PFT), BAL analysis, and lung histology. HRCT scans per-
formed at the time of ILD diagnosis and during follow-up
were reviewed by an experienced radiologist (CDB) and two
pulmonologists (FS and AB). The following features were
noted: alveolar consolidations, ground glass opacities,
septal thickening, subpleural reticulations, honeycombing,
bronchiectasis, bronchial thickening and pleural abnor-
malities. To assess lesion distribution, each lung was
divided into three areas (upper/medial/lower) from the
lung apices to the domes of the diaphragm. Conclusions
were reached by consensus. The clinical data, PFT and BAL
findings were collected. An extensive search for viruses (as
described in the e-appendix), bacteria (direct examination
and culture) and fungi (immunofluorescence and molecular
biology for Pneumocystis jiroveci; direct examination andculture for other species) was performed on the BAL. When
bronchoscopy could not be performed, bacteria and fungi
were searched for in the sputum, P. jiroveci was searched
for in induced sputum samples and respiratory viruses were
searched for in nasal aspirates (e-appendix). The total and
differential cell counts in the BAL were analyzed. Pulmo-
nary function tests were performed using a body plethys-
mograph (Jaeger Masterscreen Body; Jaeger, GmBH;
Wurzburg, Germany). The diffusing capacity of carbon
monoxide (DLCO) was measured using the single breath
method, and the results were adjusted to the last available
hemoglobin level. Predictive values were determined as
previously described [27]. Obstruction was defined as an
FEV1/FVC ratio <0.7 [28], and restriction was defined as a
TLC < 80% of the predicted value. A DLCO <80% of the
predicted value was considered abnormal. An experienced
pathologist (VM) analyzed the lung tissue specimen from
patients who underwent a surgical lung biopsy. The diag-
nosis and severity of GVHD were reported based on the
clinical grading scores [29,30].
Statistical analyses
Descriptive statistics are presented as the median and
inter-quartile range (IQR) [IQR: 25 to 75th percentiles] for
continuous parameters and as the number and percentage
for non-continuous and qualitative parameters. Survival
after ILD diagnosis and ILD incidence were estimated using
the KaplaneMeier method. The prognostic analysis of post-
ILD survival was univariate, based on a log rank test for
non-continuous parameters or logistic regression with a Cox
model for continuous parameters. Given the sample size
and number of observed events, no multivariate analyses
were performed. Every statistical analysis had a bilateral
formulation, and P < 0.05 was considered significant.
Results
Patient characteristics
Between 2001 and 2010, 1277 allogeneic HSCTs were per-
formed in our center, including 35% using a myeloablative
conditioning regimen, and 65% using a nonmyeloablative
conditioning regimen with stem cell sources as followed:
60% peripheral blood stem cells, 25% bone marrow and 15%
cord blood.
Thirty-one allogeneic HSCT recipients were identified as
having a noninfectious ILD (2.4%). Three patients from a
previous study were included [11]. Nine additional patients,
referred to our department because of an ILD during the
study period, were included. Sixteen patients were diag-
nosed between 2001 and 2007 and 24 patients between
2008. The clinical characteristics of the patients are sum-
marized in Table 1. All ILD occurred within the first three
years after allogeneic HSCT. The median time from trans-
plantation to ILD was 11.3 months [IQR: 5.9e19.2]. Most of
the patients had received prior chemotherapy, and 30% had
experienced a prior autologous transplantation. The donor
hematopoietic stem cell sources were peripheral blood
stem cells in 75% of the cases, and the conditioning regimen
was non-myeloablative in 57.5% of the cases.
Table 1 Clinical characteristics of the 40 patients at ILD
diagnosis.
Clinical variables Median [IQR];
N (%)
Age at transplant, years 40.5 [27.5e51.5]
Male 28 (70)
Smoking history 17 (43)
Age at ILD, years 40.6 [28.5; 51.8]
Time from transplantation
to ILD, months
11.3 [5.9e19.2]
History of an infectious
pneumonia in the time
between the transplant and ILD
11 (27.5)
Hematological diseases
AL 15 (37.5)
CML 2 (5)
Lymphoma 13 (32.5)
Myeloma 2 (5)
Othersa 8 (20)
Status of disease at time of transplant
Complete response 28 (70)
Relapse 2 (5)
Chronic phase/partial response 2 (5)
NA 8 (20)
Stem cell source
PBSCs 30 (75)
Bone marrow 9 (22.5)
Cord blood 1 (2.5)
Donor HLA status
Related 23 (57.5)
Unrelatedb 17 (42.5)
Conditioning regimen
Non-myeloablative 23 (57.5)
Busulfan-based 10 (25)
TBI 25 (62.5)
GVHD prophylaxis
Cyclosporine alone 6 (15)
Cyclosporine-mycophenolate mofetil 24 (60)
Cyclosporine-methotrexate 10 (25)
Acute GVHD 22 (55)
Grade 2 14 (35)
Chronic GVHD 28 (70)
Limited 21 (52.5)
Extensive 7 (17.5)
ILD, interstitial lung disease; AL, acute leukemia; CML, chronic
myeloid leukemia; NA, not available; HLA, human leukocyte
antigen; PBSCs, peripheral blood stem cells; TBI, total body
irradiation; GVHD, graft-versus-host disease.
a Myelodysplasic syndrome, myeloproliferative disease other
than CML, aplastic anemia.
b 10/10 and 9/10 allelic unrelated donors and cord blood
transplant.
Table 2 Lung HRCT findings in patients at diagnosis of ILD
after allogeneic hematopoietic stem cell transplantation.
Imaging finding N (%) of patients
(N Z 40)
Alveolar consolidations 30 (75)
Bilateral 19 (63)
Ground glass opacities 29 (72)
Bilateral 24 (83)
Involvement of >3 lung areasa,b 15 (37)
Exclusive upper lung area involvementb 5 (12)
Exclusive lower lung area involvementb 9 (22)
Reticulation 3 (7)
Septal thickening 1 (2)
Honeycombing 1 (2)
Bronchial thickening 4 (10)
Pneumomediastinum 3 (7)
a Each lung was divided into three areas: upper, medial and
lower.
b Concerns alveolar consolidation and ground glass opacity.
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Clinical characteristics
The most frequent clinical symptoms were dyspnea
(n Z 35, 87.5%; New York Heart Association (NYHA)  3:
nZ 12, 40%), fever (nZ 20, 50%), and cough (nZ 24, 60%).The median time from the onset of symptoms to ILD diag-
nosis was 15 days [IQR: 2e71].
At the time of ILD diagnosis, 27 patients (67.5%) were
receiving systemic immunosuppressive treatment calci-
neurin inhibitors (n Z 12), mycophenolate mofetil
(n Z 9), everolimus (n Z 1), etanercept (n Z 1) or
imatinib (n Z 1); 16 were receiving a single drug, and 10
were receiving two or more drugs. Forty percent of the
patients were receiving systemic steroids (median dose of
prednisone; 25 mg per day, [IQR: 20e40]) for coexisting
GVHD.
Overall, 34 patients (85%) had a history of GVHD, either
acute and/or chronic (Table 1). Chronic GVHD was present
in 28 patients (70%) at the time of ILD diagnosis and
involved the skin and/or mucosa (42.5%), the gut (20%) or
the liver (17.5%; Table 1). Four more patients developed
GVHD after the ILD diagnosis.
No patients had a history suggestive of an ILD associated
with an inhalational exposure.
Thoracic imaging
The HRCT characteristics of ILD are summarized in Table 2.
Two different HRCT patterns were identified according to
the predominance of alveolar consolidations (n Z 22, 55%,
Fig. 1A) or ground glass opacities (n Z 18, 45%, Fig. 1B).
Other HRCT abnormalities were infrequent. Patients with a
ground glass opacity pattern or alveolar consolidation
pattern did not differ in their clinical characteristics or
time from allogeneic HSCT to ILD diagnosis.
Lung function
The results of the pulmonary function tests (PFTs) are
presented in Table 3. Lung volumes and DLCO were available
for 29 and 18 patients, respectively. At ILD diagnosis, 24
patients (83%) had a restrictive lung disease (RLD), eight
patients (28%) had an obstructive lung disease (OLD) and
four patients (14%) had a mixed pattern. Only two patients
(7%) had normal lung volumes. The DLCO was decreased in
all of the patients tested.
Figure 1 Lung HRCT patterns of ILD after allogeneic hematopoietic stem cell transplantation. Two patterns were identified: one
with predominant alveolar opacities (A), and one with predominant ground glass opacities (B).
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BAL was performed in 30 patients. The total and differen-
tial cell counts are shown in Table 4. Except for three pa-
tients (10%) who had normal BAL cell counts, all patients
had an alveolitis. Lymphocytic alveolitis (defined by a
lymphocyte count 15% of total cells) was the most
frequent and was found in 20 patients (67%). Among these
patients, the median percentage of alveolar lymphocytes
was 40% [IQR: 21e56%] and seven patients had a concomi-
tant neutrophil count 10% of total cells. Three other pa-
tients had a neutrophil count 10% of total cells (median
20%, [IQR: 15e33%]). Four patients had an eosinophil count
10% of total cells, including two with an eosinophil count
20% of total cells, suggesting an eosinophilic pneumonia.Both PFT and BAL results were similar whether patients
had a ground glass opacities HRCT pattern or an alveolar
consolidation pattern.
Lung histology
Eleven lung biopsies were available for 10 patients. Four
patients had CT scan-guided percutaneous lung biopsies,
and seven patients had surgical lung biopsies (six with
video-assisted thoracoscopy). Four of these 10 patients
(40%) experienced postoperative morbidity or mortality;
two patients required prolonged chest tube aspiration (one
required another surgery), and two patients died within 15
days following surgery (one from respiratory failure and the
other from septic shock with multisystem organ failure). A
Table 3 Pulmonary function testing in overall patients and according to the lung HRCT pattern at the time of ILD diagnosis.
Median [IQR] FEV1 FVC FEV1/FVC
%
TLC DLCO
(L) % pred (L) % pred (L) % pred % pred
All patients
(n Z 29)
1.805
[1.54e2.39]
53
[42e72]
2.38
[1.82e2.85]
52
[42.5e72]
81.9
[71.5e87]
4.05
[3.53e5.17]
63
[58e77]
41
[36e47]
Ground glass patterna
(n Z 13)
1.675
[1.54e2.25]
52.5
[42.6e61.2]
2.18
[1.82e2.55]
52
[43.9e60.5]
81.9
[70.6e88.9]
4.04
[3.65e5.18]
63.5
[60.1e74.2]
43
[36e47]
Alveolar consolidations
patterna
(n Z 16)
2.065
[1.54e2.51]
53
[42e77.5]
2.485
[2.03e3.03]
56
[42.7e80.2]
81.65
[72.5e85.5]
4.09
[3.53e4.33]
63
[57e79]
39
[37e44]
a Lung CT scan pattern; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; TLC, total lung capacity; DLCO, diffusing
capacity of carbon oxide; pred, predicted.
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patients and consisted of DAD (n Z 2), nonspecific inter-
stitial pneumonia (NSIP) (n Z 2), OP (n Z 2) and LIP
(nZ 1). Patients diagnosed with DAD had either an alveolar
consolidation or a ground glass opacities HRCT pattern. The
two patients diagnosed with OP and the patient diagnosed
with LIP had an alveolar consolidations pattern; both of the
patients diagnosed with NSIP had a ground glass opacities
HRCT pattern.
Treatment and outcome
The median follow-up after diagnosis of ILD was 9.3 months
[IQR: 2.1e32]. The patients of both HRCT phenotypes were
treated similarly. Thirty-five patients (87.5%) received sys-
temic steroids for the treatment of ILD (introduction or
increase), and 13 of these patients (32.5%) received high-
dose intravenous steroids (pulse methylprednisolone
5e10 mg/kg for 3 days). One patient received cyclophos-
phamide together with pulse methylprednisolone. Five
patients did not receive steroids at the time ILD was diag-
nosed. Among these five patients, one patient finally
received high-dose pulsed methylprednisolone one year
after ILD diagnosis because of progressive lung disease;
three patients required steroids 2e6 months after the ILD
diagnosis for extra thoracic GVHD. One patient presented
spontaneous resolution of ILD.Table 4 Bronchoalveolar lavage cell counts in overall
patients and according to the lung HRCT pattern.
Median [IQR] Total cell
count/mm3
Ma
%
Ly
%
Neu
%
Eo
%
All patients
(n Z 30)
280
[180e460]
54
[35e82]
20.5
[8e48]
6
[2e15]
0
[0e3]
Ground glass
patterna
(n Z 15)
250
[150e280]
67
[25e88]
19
[5e48]
5
[1e11]
0
[0e5]
Alveolar
consolidations
patterna
(n Z 15)
315
[225e465]
50
[35e77]
23
[18e52]
7
[2e18]
0
[0e2]
a Lung CT scan pattern; Ma, macrophages; Ly, lymphocytes;
Neu, neutrophils; Eo, eosinophils.Thirteen patients died (33%). Ten patients died of res-
piratory failure; these patients were receiving systemic
steroids for ILD treatment. The lung histology available for
two of these patients showed DAD for one and NSIP for the
other. The three other patients died of refractory gut
cGVHD associated with severe sepsis, septic shock and en-
cephalopathy syndrome. The survival rate was estimated at
77% [IQR: 64e92%], 70% [IQR: 56e88%] and 61% [IQR:
45e82%] at 6, 12 and 24 months, respectively, after ILD
diagnosis (Fig. 2).
Evolution of HRCT and PFT
Although the overall prognosis of ILD was poor, a significant
number of patients had a favorable outcome regarding
HRCT and PFT. We did not find any association between the
evolution of both HRCT and PFT and the HRCT scan pattern
at ILD diagnosis.
Among the survivors, at least two serial HRCT scans were
available for 18 patients (alveolar consolidations HRCTFigure 2 The estimated overall survival distribution after ILD
diagnosis in the study population. The dashed lines represent
the 95% CI of survival estimates over time.
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(n Z 7)). For these patients, the last available HRCT scan
was performed at a median time of 10.3 months after ILD
diagnosis [IQR: 2e23]. At last follow-up, complete resolu-
tion of radiological abnormalities was observed in five pa-
tients (alveolar consolidations pattern (n Z 4)) and
persisted in 13 patients (ground glass opacities pattern
(n Z 6), alveolar consolidations (n Z 7)). After being
characterized as having a particular phenotype by a CT scan
at the time of diagnosis, none of the patients evolved to the
other phenotype.
All the patients who had PFT at ILD diagnosis had two or
more PFTs during the follow-up with a similar distribution
between both HRCT pattern; for these patients, the last
available PFT was performed at a median time of 7 months
[IQR: 3e18] after the first PFT. Fourteen patients (45%)
showed greater than 10% improvement of FVC or FEV1
relative to the baseline.
Prognostic analysis
In the univariate analysis, no prognostic factor was identi-
fied to be associated with survival (e-Table 1). The patients
with an alveolar consolidation pattern tended to have
better survival than those with a ground glass opacity
pattern (78% vs. 60% at 12 months, 71% vs. 48% at 24
months), although the difference did not reach statistical
significance (p Z 0.19; e-Fig. 1).
Discussion
This retrospective study is the largest series on allogeneic
post-HSCT non-infectious ILD. Our study highlights the ex-
istence of post-allogeneic HSCT non-infectious ILD and
provides new insights into the clinical characteristics of this
complication. Previous studies have focused on epidemio-
logical data and anecdotal reports. We observed the
following: 1) post-allogeneic HSCT ILD typically occur
within the first 3 years after transplantation and are
frequently associated with extra pulmonary GVHD mani-
festations; 2) ILD include different histological entities; 3)
two distinct lung HRCT patterns were observed according to
the predominance of ground glass opacities or alveolar
consolidations; 4) lung function restriction and BAL lym-
phocytic alveolitis were frequent; and 5) the prognosis was
globally poor, although in some cases, ILD might improve or
resolve with corticosteroids.
In the context of allogeneic HSCT, the occurrence of ILD
is often attributed to idiopathic pneumonia syndrome (IPS)
or to OP [4,31]. IPS is not a well-defined pulmonary disease
and includes various conditions [31,32]. The diagnosis of
IPS, which has recently been reviewed, relies on diffuse
lung opacities on the chest X-ray and the exclusion of
several diagnoses, such as lung infection or pulmonary
edema [31]. The median time of onset for IPS is reported to
be 19 days (range, 4e106 days) after HSCT. The intensity
and type of HSCT conditioning have been associated with
the development of IPS, which is consistent with data
generated from mouse models [31]. The ILD described in
our study differ in various respects from IPS. ILD occurred
later after transplantation, predominantly in patients whounderwent non-myeloablative conditioning. Only 60% of our
patients underwent pre-transplant total body irradiation,
and none of our patients received carmustine; both of
these factors are associated with IPS. Thus, the ILD we
described do not match the current IPS criteria. Conversely,
the time of onset after the HSCT and the clinical, pulmo-
nary and radiological characteristics of some of our patients
were similar to the characteristics described in cases of
post-allogeneic HSCT OP [13,33]. However, based on the
lung biopsy results, other ILD entities (NSIP, DAD and LIP)
were observed in our patients.
At present, only biopsy-proven BO has been firmly
recognized as a manifestation of lung GVHD based on
epidemiological studies that show a strong association be-
tween BO and extra-thoracic chronic GVHD. In several
studies, OP has also been associated with GVHD [4,13,15]. A
feature of our findings is that almost all patients who
developed late onset ILD had a history of acute and/or
chronic GVHD. Unfortunately, due to the retrospective
design of our study, we could not evaluate the incidence of
GVHD in our population of HSCT recipients who did not
develop ILD during the study period. Thus, although our
findings suggest that the ILD spectrum may reflect lung
GVHD, we could not formally conclude. However, the
presence of an OLD in some of our patients, suggesting BO
associated with ILD, further strengthens this hypothesis.
Although the history of the patients was not suggestive, the
role of drug pulmonary toxicity in patients receiving mul-
tiple treatments cannot be formally ruled out.
One finding of our study is that, conversely to what is
known for the treatment of BO [6,34], a significant pro-
portion of our patients who were treated with steroids had
either complete resolution of their ILD or a significant
improvement in their PFT. These data emphasize the
importance of identifying these ILD to promptly administer
steroids. However, only a randomized study could demon-
strate the efficacy of steroids in post allogeneic non-
infectious ILD.
The retrospective design and the relatively small num-
ber of patients did not allow us to reach firm conclusions on
several points. First, we could not correlate the radiological
and clinical diagnosis with the underlying histological dis-
ease because of the small number of patients who under-
went a surgical lung biopsy. Of note, in our few patients
who underwent a lung biopsy, alveolar consolidations HRCT
pattern could be associated with either DAD, OP or LIP
whereas ground glass opacities pattern was associated with
NSIP or DAD. Second, during the follow-up period, we did
not report any changes in the HRCT scan patterns. However,
follow up HRCT scans were not available for all of the pa-
tients. Thus, we could not firmly exclude that both HRCT
scan patterns are a spectrum of the same lung disease
entity. Third, we could not identify any prognostic factors,
although the patients with an alveolar consolidation
pattern tended to have better survival than the patients
with a ground glass opacities pattern.
In summary, because of the increasing number of long-
term HSCT survivors, an understanding of new late onset
noninfectious complications is important. Herein, we
described the characteristics of ILD occurring after alloge-
neic HSCT according to the usual approach of ILD. As typi-
cally occurs in clinical practices, the majority of these
1532 F. Schlemmer et al.patients did not undergo lung biopsies. Our data provide
information regarding the management of these patients.
Further studies are needed to clarify the physiopathology,
identify the risk factors and optimize the treatment of
these lung disorders to improve the prognosis.
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